Blog

Infantile epileptic spasm syndrome (IESS) comprises a spectrum of disorders characterized by epileptic spasms (ES). The developmental prognosis is poor, varying based on etiology, with 9–12% of patients exhibiting normal development [1–3]. The standard treatments for IESS include adrenocorticotropic hormone (ACTH) therapy, prednisolone, and vigabatrin (VGB). Previous studies have investigated the efficacy of IESS therapies by comparing two distinct groups: cryptogenic and symptomatic. Findings from these studies suggest that cryptogenic patients exhibit higher treatment efficacy than symptomatic patients [4–6].